Education and Training

Radiation Therapy Residency

Medical Students

Medical Physics Residency

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age

The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT).

Stanford is currently not accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • biological: Viaskin Peanut 250 mcg
  • biological: Viaskin Peanut 100 mcg
  • biological: Placebo

Eligibility


Key Inclusion Criteria:

   - Male or female from 1-3 years of age;

   - Physician-diagnosed peanut allergy;

   - Peanut-specific IgE level > 0.7 kU/L;

   - Positive peanut SPT with a largest wheal diameter ≥ 6 mm;

   - Positive DBPCFC at ≤ 300 mg peanut protein;

Key Exclusion Criteria:

   - Uncontrolled asthma;

   - History of severe anaphylaxis to peanut;

   - Prior immunotherapy to any food or other immunotherapy;

   - Generalized severe dermatologic disease;

Ages Eligible for Study

1 Year - 3 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Sayantani Sindher
650-724-0293
Not Recruiting